Promega, J2211, PD-1+TIGIT Combination Bioassay

Measure the ability of biologics to block immune checkpoint signals
PD-1 and TIGIT are both immune inhibitory receptors that are expressed on T cells. Engagement of PD-1 by PD-L1 on an adjacent cell inhibits TCR signaling and TCR-mediated proliferation, transcriptional activation and cytokine production. The ligand for TIGIT is CD155. TIGIT negatively regulates NK cell killing and T cell activation by competing with CD226 for binding to CD155 and by directly interfering with CD226 homodimerization.
Preclinical cancer studies suggest that targeted therapies that simultaneously block PD-1 and TIGIT are superior to those that block either pathway alone. The PD-1+TIGIT Combination Bioassay reflects the mechanism of action (MOA) of biologics designed to block the PD-1/PD-L1 and TIGIT/CD155 interactions.
Control Ab, Anti-TIGIT, is a mouse monoclonal antibody that shows blocking activity of TIGIT with its ligand, CD155. It is intended for use as a control with the PD-1+TIGIT Combination Bioassay and the TIGIT/CD155 Blockade Bioassay. These assays can be used to measure the potency and stability of antibodies and other biologics designed to block the TIGIT/CD155 interaction.
TIGIT Negative Cells are for use as a negative control in the TIGIT/CD155 Blockade Bioassay. TIGIT Negative Cells are activated by engagement of the TCR/CD3 complex and costimulatory receptor CD28 co-engagement.